Medicines and Healthcare products Regulatory Agency (MHRA)

10-2 Market Towers, 1 Nine Elms Lane, London, SW8 5NQ, UK
Telephone: +44 (0)207 084 2000 (weekdays 0900-1700)
Fax: +44 (0)207 084 2353
E-mail: info@mhra.gsi.gov.uk

Patient Information Leaflet last updated on the eMC: 26/01/2010
PIL Oseltamivir 30mg Hard Capsules

The patient information leaflet you have selected is in PDF format.

View Patient Information Leaflet (0.117MB)

Can't read the PDF? Visit adobe.com and download the Adobe Acrobat Reader.


More information about this product

Link to this document from your website: http://emc.medicines.org.uk/medicine/22730/PIL/Oseltamivir 30mg Hard Capsules/


For information on the use of Tamiflu

Contact:
Roche Products Limited
Hexagon Place, 6 Falcon Way, Shire Park, Welwyn Garden City, Hertfordshire, AL7 1TW
Telephone: +44 (0)1707 366 000
Fax: +44 (0)1707 338 297
Medical Information Direct Line: +44 (0)800 328 1629
Medical Information e-mail: medinfo.uk@roche.com
Medical Information Fax: +44 (0)1707 384555

Adverse events should be reported. Reporting forms and information can be found at http://www.yellowcard.gov.uk
Adverse events should also be reported to Roche Products Limited.
Please contact Roche Drug Safety Centre on 01707 367554.

Black Triangle

This medicine is monitored intensively by the CHM and MHRA

Active Ingredients/Generics

 
   oseltamivir phosphate


© 2010 Datapharm Communications Ltd

Go to www.medicines.org.uk